AMLo Biosciences
AMLo is developing prognostic tests for cancers with unmet needs. Its first product is an immunohistochemical test for non-ulcerated, cutaneous melanomas which can accurate identify those tumours at low risk of recurrence / spread, reducing patient anxiety associated with cancer.
![](https://www.ascension.vc/wp-content/uploads/2024/02/Screenshot-2024-02-23-at-12.22.00.png)